Skip to main content
Clinical Trials/NCT05332782
NCT05332782
Recruiting
Not Applicable

Outcomes of Patients tReated wIth Mitral Transcatheter Edge-to-edge Repair for Primary Mitral Regurgitation Registry

Universitätsklinikum Hamburg-Eppendorf6 sites in 3 countries2,000 target enrollmentMarch 1, 2022

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Mitral Regurgitation
Sponsor
Universitätsklinikum Hamburg-Eppendorf
Enrollment
2000
Locations
6
Primary Endpoint
All-cause mortality
Status
Recruiting
Last Updated
4 years ago

Overview

Brief Summary

This multinational, non-interventional, investigator-initiated, retrospective study aims to investigate outcomes of patients, who underwent mitral valve transcatheter edge-to-edge repair (M-TEER) for primary mitral regurgitation (PMR).

Registry
clinicaltrials.gov
Start Date
March 1, 2022
End Date
January 1, 2026
Last Updated
4 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • clinically significant primary mitral regurgitation
  • patient underwent M-TEER
  • echocardiography data at baseline, procedure and follow-up
  • follow-up of at least 12 months
  • Exclusion Criteria
  • age under 18 years

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

All-cause mortality

Time Frame: 12 months

Incidence of death from any cause.

Cardiovascular mortality

Time Frame: 12 months

Incidence of cardiovascular death, defined as death attributable to myocardial ischemia and infarction, heart failure, cardiac arrest because of other or unknown cause, or cerebrovascular accident.

Rehospitalization for congestive heart failure

Time Frame: 12 months

Incidence of new-onset or worsening signs and symptoms of heart failure that required urgent therapy and resulted in hospitalization, e.g. as assessed by patient interviews or medical records.

Re-do mitral valve procedure

Time Frame: 12 months

Incidence of unplanned surgical (mitral valve repair or replacement) or transcatheter re-intervention (re-do transcatheter edge-to-edge repair), e.g. as assessed by patient interviews or medical records.

Secondary Outcomes

  • Residual mitral regurgitation(12 months)
  • MVARC (Mitral Valve Academic Research Consortium) Technical success(1 day (at exit from the catheterization laboratory))
  • Functional success(1 day (at exit from the catheterization laboratory))

Study Sites (6)

Loading locations...

Similar Trials